As of May 31
| +0.21 / +0.41%|
The 21 analysts offering 12-month price forecasts for Teva Pharmaceutical have a median target of 75.00, with a high estimate of 100.00 and a low estimate of 59.00. The median estimate represents a +44.59% increase from the last price of 51.87.
The current consensus among 28 polled investment analysts is to Buy stock in Teva Pharmaceutical. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.